Erasca, Inc. (NASDAQ:ERAS) Receives $20.64 Average Price Target from Brokerages

Erasca, Inc. (NASDAQ:ERAS) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $21.6364.

A number of research firms have commented on ERAS. Wall Street Zen downgraded shares of Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Morgan Stanley increased their price target on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a report on Monday. HSBC set a $20.00 price target on Erasca in a research note on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Finally, Mizuho reduced their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th.

Erasca News Roundup

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Several firms, including Rosen Law Firm, Berger Montague, Bernstein Liebhard, and others, reiterated that a securities class action has been filed against Erasca and that investors who bought shares during the class period may seek lead-plaintiff status. ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Some allegations in the litigation are particularly damaging, claiming Erasca misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection, and failed to disclose risks such as patent infringement exposure and a patient death. ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
• Neutral Sentiment: One market note said Morgan Stanley sees Erasca’s stock price as having room to rise, offering a more constructive view that may help offset some of the legal overhang. Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Institutional Investors Weigh In On Erasca

Large investors have recently made changes to their positions in the company. VR Adviser LLC lifted its stake in shares of Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after purchasing an additional 1,640,867 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in shares of Erasca by 4.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock worth $52,672,000 after buying an additional 599,078 shares during the last quarter. Vanguard Group Inc. grew its position in Erasca by 0.9% during the third quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock valued at $27,930,000 after buying an additional 116,235 shares during the period. Vivo Capital LLC grew its position in Erasca by 31.0% during the first quarter. Vivo Capital LLC now owns 12,151,480 shares of the company’s stock valued at $196,611,000 after buying an additional 2,878,052 shares during the period. Finally, Siren L.L.C. increased its holdings in Erasca by 28.4% during the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company’s stock valued at $181,932,000 after buying an additional 2,486,997 shares during the last quarter. 67.78% of the stock is currently owned by institutional investors.

Erasca Stock Up 0.7%

Shares of NASDAQ ERAS opened at $19.51 on Monday. The firm’s 50-day moving average price is $15.08 and its 200-day moving average price is $13.77. Erasca has a 52-week low of $1.33 and a 52-week high of $24.28. The company has a market cap of $6.07 billion, a PE ratio of -20.98 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, equities research analysts anticipate that Erasca will post -0.54 EPS for the current fiscal year.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.